Evidence map›Paper›PMID 38662699›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2024

Improving the Cost-efficiency of Preventive Chemotherapy: Impact of New Diagnostics on Stopping Decisions for Control of Schistosomiasis.

Luc E Coffeng, Matthew Graham, Raiha Browning, Klodeta Kura, Peter J Diggle, Matthew Denwood, Graham F Medley, Roy M Anderson, Sake J de Vlas

Open access · hybridAbstract read
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.1field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. New Tools and Nuanced Interventions to Accelerate Achievement of the 2030 Roadmap for Neglected Tropical Diseases.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 3 countries.

Luc E CoffengDepartment of Public Health, Erasmus Medical Center, University Medical Center Rotterdam, The Netherlands.ORCID 0000-0002-4425-2264
Matthew GrahamBig Data Institute, Li Ka Shing Centre for Health Information and Discovery, University of Oxford.
Raiha BrowningDepartment of Statistics, University of Warwick.
Klodeta KuraLondon Centre for Neglected Tropical Disease Research, School of Public Health, Imperial College London.
Peter J DiggleCentre for Health Informatics, Computing, and Statistics, Lancaster University Medical School, United Kingdom.
Matthew DenwoodDepartment of Veterinary and Animal Sciences, University of Copenhagen, Denmark.
Graham F MedleyDepartment of Global Health and Development, Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, United Kingdom.
Roy M AndersonLondon Centre for Neglected Tropical Disease Research, School of Public Health, Imperial College London.
Sake J de VlasDepartment of Public Health, Erasmus Medical Center, University Medical Center Rotterdam, The Netherlands.
Erasmus MC · NLLondon Centre for Neglected Tropical Disease Research · GBLancaster University · GBLondon School of Hygiene & Tropical Medicine · GBUniversity of Copenhagen · DKUniversity of Warwick · GB

Funding

Medical Research Council MR/R015600/1
6 · The paper itself

Abstract

backgroundControl of schistosomiasis (SCH) relies on the regular distribution of preventive chemotherapy (PC) over many years. For the sake of sustainable SCH control, a decision must be made at some stage to scale down or stop PC. These "stopping decisions" are based on population surveys that assess whether infection levels are sufficiently low. However, the limited sensitivity of the currently used diagnostic (Kato-Katz [KK]) to detect low-intensity infections is a concern. Therefore, the use of new, more sensitive, molecular diagnostics has been proposed.

methodsThrough statistical analysis of Schistosoma mansoni egg counts collected from Burundi and a simulation study using an established transmission model for schistosomiasis, we investigated the extent to which more sensitive diagnostics can improve decision making regarding stopping or continuing PC for the control of S. mansoni.

resultsWe found that KK-based strategies perform reasonably well for determining when to stop PC at a local scale. Use of more sensitive diagnostics leads to a marginally improved health impact (person-years lived with heavy infection) and comes at a cost of continuing PC for longer (up to around 3 years), unless the decision threshold for stopping PC is adapted upward. However, if this threshold is set too high, PC may be stopped prematurely, resulting in a rebound of infection levels and disease burden (+45% person-years of heavy infection).

conclusionsWe conclude that the potential value of more sensitive diagnostics lies more in the reduction of survey-related costs than in the direct health impact of improved parasite control.

Indexed as

Cost-Benefit AnalysisParasite Egg CountSchistosoma mansoniSchistosomiasis mansoniAdolescentAdultAnimalsAnthelminticsChemopreventionChildFemaleHumansMaleSchistosomiasisSensitivity and SpecificityYoung AdultAnthelminticsbilharziacost-efficiencydecision criteriondiagnostic performancefecal smear

Identifiers

PMID38662699
PMCPMC11045014
OpenAlexW4395467470

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.